AMENDED CLAIM SET:

1. (*Currently amended*) A peptide comprising a portion of a protein selected from the group consisting of plasminogen, endostatin, VEGF, ~~FLT-1~~ and KDR/FLK-1, wherein said peptide is of length from 7-20 amino acids long and wherein said peptide exhibits an IC_{50} of 20 μM or less in a bovine aorta endothelial cell proliferation assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 30% at a dose of 50 μg/coverslip.

2. (*Original*) The peptide of claim **1** that exhibits an IC_{50} of 20 nM to 20 mM in a bovine aorta endothelial cell assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 50% at a dose of 10 to 25 μg/coverslip.

3. (*Original*) The peptide of claim **1** comprising a portion of a kringle domain of plasminogen.

4. (*Original*) The peptide of claim **3**, wherein said portion of a kringle domain is represented by residues 27-41 of a kringle domain of human or mouse plasminogen.

5. (*Original*) The peptide of claim **3**, wherein said portion of a kringle domain is represented by residues 29-38 or residues 29-39 of a plasminogen.

6. (*Original*) The peptide of claim **1** that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

7. (*Currently amended*) The peptide of claim **1** that is derived from endostatin, VEGF, ~~FLT-1~~ and KDR/FLK-1 and has a length of from 9 to 20 amino acids long.

8. (*Original*) The peptide of claim **7** that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

9. (*Currently amended*) The peptide of claim **1**, comprising a peptide having an amino acid sequence selected from the group consisting of ~~SEQ. ID. NOs.~~ SEQ ID NOs 1-3, 11-33, ~~35-38, 40-41 and 44-50~~ 35, and 47-50.

10. (*Currently amended*) The peptide of claim **1**, comprising a peptide having an amino acid sequence selected from the group consisting of ~~SEQ. ID. NOs.~~ SEQ ID NOs 1-3, 11, 12, ~~29-36 and 38-39~~ and 29-35.

11. (*Cancelled*).

12. (*Cancelled*).

13. (*Original*) A pharmaceutical composition comprising a peptide according to claim **1** and a pharmaceutically acceptable carrier.

14. (*Original*) The composition according to claim **13**, wherein said composition provides a unit dose of from 20 μg/kg/day to 2 mg/kg/day.

15. (*Currently amended*) A pharmaceutical composition comprising a peptide according to claim **10** ~~11~~ and a pharmaceutically acceptable carrier.

16. (*Original*) The composition according to claim **15**, wherein said composition provides a unit dose of from 20 μg/kg/day to 2 mg/kg/day.

17. (*Cancelled*).

18. (*Cancelled*).

19. (*Original*) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or

presenting undesired angiogenesis an effective amount of the composition of claim **13** to a subject.

20. (*Original*) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or presenting undesired angiogenesis an effective amount of the composition of claim **15** to a subject.

21. (*Cancelled*).

22. (*Currently amended*) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim **13**.

23. (*Currently amended*) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering the composition of claim **15** to a subject at risk for or presenting a tumor.

24. (*Cancelled*).

25. (*New*) The peptide of claim **1**, comprising the peptide having the amino acid sequence of SEQ ID NO:30.

26. (*New*) A pharmaceutical composition comprising the peptide according to claim **25** and a pharmaceutically acceptable carrier.

27. (*New*) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or presenting undesired angiogenesis an effective amount of the composition of claim **26** to a subject.

28. (*New*) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim **25**.